Ingevity (NGVT) Stock Price, News & Analysis

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ingevity in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NGVT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NGVT, but not buy additional shares or sell existing shares.
View NGVT analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued 1 year price objectives for Ingevity's shares. Their NGVT share price targets range from $43.00 to $53.00. On average, they expect the company's share price to reach $48.75 in the next twelve months. This suggests a possible upside of 11.2% from the stock's current price.
View analysts price targets for NGVT or view top-rated stocks among Wall Street analysts.

Ingevity's stock was trading at $47.22 at the start of the year. Since then, NGVT stock has decreased by 7.2% and is now trading at $43.84.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our NGVT earnings forecast.

Ingevity Co. (NYSE:NGVT) announced its quarterly earnings results on Wednesday, February, 21st. The company reported $0.21 EPS for the quarter, beating the consensus estimate of ($0.13) by $0.34. The firm had revenue of $371.70 million for the quarter, compared to analysts' expectations of $336.74 million. Ingevity had a negative net margin of 0.32% and a positive trailing twelve-month return on equity of 20.75%. Ingevity's revenue was down 3.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.57 earnings per share.

ETFs with the largest weight of Ingevity (NYSE:NGVT) stock in their portfolio include Invesco S&P SmallCap Materials ETF (PSCM), Putnam BioRevolution ETF (SYNB), ProShares Smart Materials ETF (TINT) and Thrivent Small-Mid Cap ESG ETF (TSME).Avantis U.S. Small Cap Equity ETF (AVSC).

Ingevity issued an update on its FY 2024 earnings guidance on Wednesday, February, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.4 billion-$1.6 billion, compared to the consensus revenue estimate of $1.5 billion.

2 employees have rated Ingevity Chief Executive Officer John Fortson on Glassdoor.com. John Fortson has an approval rating of 100% among the company's employees. This puts John Fortson in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ingevity investors own include Pfizer (PFE), AbbVie (ABBV), General Electric (GE), Verizon Communications (VZ), WestRock (WRK), Abbott Laboratories (ABT), Boeing (BA), Costco Wholesale (COST), Dominion Energy (D) and Johnson & Johnson (JNJ).

Ingevity's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Salem Investment Counselors Inc. (0.28%) and Moody National Bank Trust Division (0.06%). Insiders that own company stock include Erik Spencer Ripple, Phillip John Platt, Richard Allen White Jr and Stuart Edward Jr Woodcock.
View institutional ownership trends.

Shares of NGVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.